Copenhagen, Denmark - November 18, 2011 - Today, Topotarget A/S (NASDAQ OMX: TOPO.CO) announced that the Board of Directors has reviewed and approved the company's interim report for the period January 1 to September 30, 2011.

The results for the period January 1 to September 30, 2011

  • Topotarget recognized revenues of DKK 74.3million during the period (DKK 95.9million in the same period in 2010)
  • A pre-tax loss of DKK 14.7million (2010: Profit of DKK 11.7million) was recorded for the period
  • The Group's net cash and cash equivalents as of September 30, 2011 totaled DKK 132.1million (DKK 205.1 million at year-end 2010)
  • Topotarget is still expecting the pre-tax loss to be within the guidance given on April 5, 2011 of DKK 20-40million for 2011 and a net cash position of DKK 110-130 million at the end of 2011
  • In respect to the CLN-17 study (CUP), Topotarget is awaiting progression-free survival (PFS) results to be availabletake place. Timing of the top-line data is expected to be reported during H1 2012

Topotarget A/S

For further information, please contact:

Francois Martelet, CEO Direct: +45 39 17 83 41; Cell: +45 51 32 83 41

Anders Vadsholt, CFO Direct: +45 39 17 83 45; Cell: +45 28 98 90 55

Annette Lykke, IR Direct: +45 39 17 83 44; Cell: +45 23 28 98 14

About Topotarget

Topotarget (NASDAQ OMX: TOPO.CO) is a Scandinavian-based international biotech company headquartered in Denmark, dedicated to improve cancer therapies. In collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses on the development in pivotal studies of its lead drug candidate, belinostat, which has demonstrated a clear anti-neoplastic effect in both hematological malignancies and solid tumors. Belinostat can be used in combination with full doses of chemotherapy, and is currently in a pivotal trial within PTCL (peripheral T-cell lymphoma) and phase II in cancer of unknown primary site (CUP). Topotarget's cancer drug target is HDAC. Totect®is a product on the market developed from Topotarget's drug discovery technology. Totect®is marketed by the company's own sales specialists in the US. The European rights to Savene®were divested in March 2010 as a consequence of the focus to develop and commercialize belinostat. For more information, please refer to www.topotarget.com.

Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Topotarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of Topotarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; Topotarget's history of incurring losses and the uncertainty of achieving profitability; Topotarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against Topotarget's products, processes and technologies; the ability to protect Topotarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.